Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. CA Cancer J. Clin. 72(1), 7–33 (2022).
  MedlineGoogle Scholar
• 2. Mao JJ, Pillai GG, Andrade CJ et al. Integrative oncology: addressing the global challenges of cancer prevention and treatment. CA Cancer J. Clin. 72(2), 144–164 (2022).
  MedlineGoogle Scholar
• 3. Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun. (Lond.) 41(12), 1331–1353 (2021).
  Google Scholar
• 4. Bodei L, Herrmann K, Schöder H et al. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat. Rev. Clin. Oncol. 19(8), 534–550 (2021).
  Google Scholar
• 5. D'Alterio C, Scala S, Sozzi G et al. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin. Cancer Biol. 60, 351–361 (2020).
  MedlineGoogle Scholar
• 6. Cheng X, Zhang H, Hamad A et al. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin. Cancer Biol. 86(Pt3) 408–419 (2022).
  Medline CASGoogle Scholar
• 7. Wang Y, Zhang H, Liu C et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J. Hematol. Oncol. 15(1), 111 (2022).
  MedlineGoogle Scholar
• 8. Bergholz JS, Wang Q, Kabraji S, Zhao JJ. Integrating immunotherapy and targeted therapy in cancer treatment: mechanistic insights and clinical implications. Clin. Cancer Res. 26(21), 5557–5566 (2020).
  Medline CASGoogle Scholar
• 9. Wang J, Wong YK, Liao F. What has traditional Chinese medicine delivered for modern medicine? Expert Rev. Mol. Med. 20, e4 (2018).
  MedlineGoogle Scholar
• 10. Kulkarni UP, Selvarajan S, Lionel S et al. Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood Cancer J. 12(1), 22 (2022).
  MedlineGoogle Scholar
• 11. Kayser S, Schlenk RF, Lebon D et al. Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study. Haematologica 106(12), 3100–3106 (2021).
  Medline CASGoogle Scholar
• 12. Liu C, Hu A, Chen H et al. The osteogenic niche-targeted arsenic nanoparticles prevent colonization of disseminated breast tumor cells in the bone. Acta Pharm. Sin. B 12(1), 364–377 (2022).
  Medline CASGoogle Scholar
• 13. Liu X, Su Y, Sun X et al. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Sci. China Life Sci. 63(11), 1744–1754 (2020).
  Medline CASGoogle Scholar
• 14. Mu M, Zhao H, Wang Y et al. Arsenic trioxide or/and copper sulfate co-exposure induce glandular stomach of chicken injury via destruction of the mitochondrial dynamics and activation of apoptosis as well as autophagy. Ecotoxicol. Environ. Saf. 185, 109678 (2019).
  Medline CASGoogle Scholar
• 15. Bell JB, Eckerdt F, Dhruv HD et al. Differential response of glioma stem cells to arsenic trioxide therapy is regulated by MNK1 and mRNA translation. Mol. Cancer Res. 16(1), 32–46 (2018).
  Medline CASGoogle Scholar
• 16. Qiu Y, Dai Y, Zhang C et al. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3ν/NF-κB feedback loop. J. Exp. Clin. Cancer Res. 37(1), 321 (2018).
  Medline CASGoogle Scholar
• 17. Zhang X, Hu B, Sun YF et al. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin. Transl. Med. 11(2), e335 (2021).
  Medline CASGoogle Scholar
• 18. Wang HY, Zhang B, Zhou JN et al. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex. Cell Death Dis. 10(6), 453 (2019).
  Medline CASGoogle Scholar
• 19. Nurchi VM, Djordjevic AB, Crisponi G et al. Arsenic toxicity: molecular targets and therapeutic agents. Biomolecules 10(2), 235 (2020).
  Medline CASGoogle Scholar
• 20. Ro SH, Bae J, Jang Y et al. Arsenic toxicity on metabolism and autophagy in adipose and muscle tissues. Antioxidants 11(4), 689 (2022).
  Medline CASGoogle Scholar
• 21. Hirano S. Biotransformation of arsenic and toxicological implication of arsenic metabolites. Arch. Toxicol. 94(8), 2587–2601 (2020). • Describes the relationship between the toxicity and biotransformation of arsenic.
  Medline CASGoogle Scholar
• 22. Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Med. Res. Rev. 42(1), 374–398 (2022). •• A recent review on the application of nanomedicine for arsenic trioxide delivery in the treatment of solid tumors.
  Medline CASGoogle Scholar
• 23. Yu M, Zhang Y, Fang M et al. Current advances of nanomedicines delivering arsenic trioxide for enhanced tumor therapy. Pharmaceutics 14(4), 743 (2022).
  Medline CASGoogle Scholar
• 24. Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu. Rev. Pharmacol. Toxicol. 47, 243–262 (2007). • Describes recent progress in arsenic toxicity.
  Medline CASGoogle Scholar
• 25. Chen QY, DesMarais T, Costa M. Metals and mechanisms of carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 59, 537–554 (2019).
  Medline CASGoogle Scholar
• 26. Sun Y, Liu G, Cai Y. Thiolated arsenicals in arsenic metabolism: occurrence, formation, and biological implications. J. Environ. Sci. (China) 49, 59–73 (2016).
  Medline CASGoogle Scholar
• 27. Herath I, Vithanage M, Seneweera S, Bundschuh J. Thiolated arsenic in natural systems: what is current, what is new and what needs to be known. Environ. Int. 115, 370–386 (2018).
  Medline CASGoogle Scholar
• 28. Wang Y, Yang XF, Zhong Y et al. Development of a red fluorescent light-up probe for highly selective and sensitive detection of vicinal dithiol-containing proteins in living cells. Chem. Sci. 7(1), 518–524 (2016).
  Medline CASGoogle Scholar
• 29. Chen FY, Yi JW, Gu ZJ et al. Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study. Nanoscale 8, 6094–100 (2016).
  Medline CASGoogle Scholar
• 30. Liu G, Song Y, Li C et al. Arsenic compounds: the wide application and mechanisms applied in acute promyelocytic leukemia and carcinogenic toxicology. Eur. J. Med. Chem. 221, 113519 (2021).
  Medline CASGoogle Scholar
• 31. Medda N, De SK, Maiti S. Different mechanisms of arsenic related signaling in cellular proliferation, apoptosis and neo-plastic transformation. Ecotoxicol. Environ. Saf. 208, 111752 (2021). • Introduces the mechanisms of arsenic in cellular proferation, apoptosis and neoplastic transformation.
  Medline CASGoogle Scholar
• 32. Siu KP, Chan JY, Fung KP. Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci. 71(3), 275–285 (2002).
  Medline CASGoogle Scholar
• 33. Sadaf N, Kumar N, Ali M et al. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci. 205, 9–17 (2018).
  Medline CASGoogle Scholar
• 34. Wang C, Ning Z, Wan F et al. Characterization of the cellular effects and mechanism of arsenic trioxide-induced hepatotoxicity in broiler chickens. Toxicol. In Vitro 61, 104629 (2019).
  Medline CASGoogle Scholar
• 35. Wang J, Peng X, Yang D et al. Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells. J. Cell Mol. Med. 26(2), 563–569 (2022).
  Medline CASGoogle Scholar
• 36. Miller WH Jr, Schipper HM, Lee JS et al. Mechanisms of action of arsenic trioxide. Cancer Res. 62(14), 3893–3903 (2002).
  Medline CASGoogle Scholar
• 37. Jiang H, Ma Y, Chen X et al. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer Sci. 101(4), 975–983 (2010).
  Medline CASGoogle Scholar
• 38. Brown E, Yedjou CG, Tchounwou PB. Cytotoxicity and oxidative stress in human liver carcinoma cells exposed to arsenic trioxide (HepG2). Met. Ions. Biol. Med. 10, 583–587 (2008).
  MedlineGoogle Scholar
• 39. Yoo DR, Chong SA, Nam MJ. Proteome profiling of arsenic trioxide-treated human hepatic cancer cells. Cancer Genomics Proteomics 6(5), 269–274 (2009).
  Medline CASGoogle Scholar
• 40. Dugo EB, Yedjou CG, Stevens JJ, Tchounwou PB. Therapeutic potential of arsenic trioxide (ATO) in treatment of hepatocellular carcinoma: role of oxidative stress in ATO-induced apoptosis. Ann. Clin. Pathol. 5(1), 1101 (2017).
  MedlineGoogle Scholar
• 41. Yuan M, Sun Z, Manthari RK et al. Arsenic-induced autophagy regulates apoptosis in AML-12 cells. Toxicol. In Vitro 72, 105074 (2021).
  Medline CASGoogle Scholar
• 42. Saretzki G. Telomeres, telomerase and ageing. Subcell. Biochem. 90, 221–308 (2018).
  Medline CASGoogle Scholar
• 43. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell 176(6), 1248–1264 (2019).
  Medline CASGoogle Scholar
• 44. Fukumura D, Kloepper J, Amoozgar Z et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325–340 (2018).
  Medline CASGoogle Scholar
• 45. Zhang F, Zhang CM, Li S et al. Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis. Mol. Med. Rep. 17(1), 1573–1582 (2018).
  Medline CASGoogle Scholar
• 46. Zhang X, Jia S, Yang S et al. Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J. Cell Biochem. 113(11), 3528–3535 (2012).
  Medline CASGoogle Scholar
• 47. Fei M, Lu M, Wang Y et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med. Oncol. 26(2), 178–185 (2009).
  Medline CASGoogle Scholar
• 48. Cai X, Yu L, Chen Z et al. Arsenic trioxide-induced upregulation of mir-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1. Cancer Biomark. 28(2), 221–230 (2020).
  Medline CASGoogle Scholar
• 49. Meng XZ, Zheng TS, Chen X et al. MicroRNA expression alteration after arsenic trioxide treatment in HepG-2 cells. J. Gastroenterol. Hepatol. 26(1), 186–193 (2011).
  Medline CASGoogle Scholar
• 50. Zhao XS, Song PL, Sun B et al. Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo. Hepatobiliary Pancreat. Dis. Int. 8(5), 510–517 (2009).
  Medline CASGoogle Scholar
• 51. Fan Z, He J, Fu T et al. Arsenic trioxide inhibits EMT in hepatocellular carcinoma by promoting lncRNA MEG3 via PKM2. Biochem. Biophys. Res. Commun. 513(4), 834–840 (2019).
  Medline CASGoogle Scholar
• 52. Cui L, Gao B, Cao Z et al. Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide. Mol. Med. Rep. 13(3), 2032–2038 (2016).
  Medline CASGoogle Scholar
• 53. Wang L, Wang R, Fan L et al. Arsenic trioxide is an immune adjuvant in liver cancer treatment. Mol. Immunol. 81, 118–126 (2017).
  Medline CASGoogle Scholar
• 54. Winter ND, Murphy RK, O'Halloran TV, Schatz GC. Development and modeling of arsenic-trioxide-loaded thermosensitive liposomes for anticancer drug delivery. J. Liposome Res. 21(2), 106–115 (2011).
  Medline CASGoogle Scholar
• 55. Wang L, Zhang J, An Y et al. A study on the thermochemotherapy effect of nanosized As₂O₃/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo. Nanotechnology 22(31), 315102 (2011).
  MedlineGoogle Scholar
• 56. Antimisiaris SG, Ioannou PV. Arsonoliposomes: preparation and physicochemical characterization. Methods Mol. Biol. 605, 147–162 (2010).
  Medline CASGoogle Scholar
• 57. Mourtas S, Papadia K, Kordopati GG et al. Synthesis of novel arsonolipids and development of novel arsonoliposome types. Pharmaceutics 14(8), 1649 (2022).
  Medline CASGoogle Scholar
• 58. Chen H, MacDonald RC, Li S et al. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J. Am. Chem. Soc. 128(41), 13348–13349 (2006). •• Describes a novel liposomal nanocarrier for controlling arsenic trioxide release.
  Medline CASGoogle Scholar
• 59. Li C, Zhang K, Liu A et al. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma. Int. J. Pharm. 609, 121209 (2021).
  Medline CASGoogle Scholar
• 60. Fatouros DG, Ioannou PV, Antimisiaris SG. Arsonoliposomes: novel nanosized arsenic-containing vesicles for drug delivery. J. Nanosci. Nanotechnol. 6(9-10), 2618–2637 (2006).
  Medline CASGoogle Scholar
• 61. Gortzi O, Papadimitriou E, Kontoyannis CG et al. Arsonoliposomes, a novel class of arsenic-containing liposomes: effect of palmitoyl-arsonolipid-containing liposomes on the viability of cancer and normal cells in culture. Pharm. Res. 19(1), 79–86 (2002).
  Medline CASGoogle Scholar
• 62. Finke H, Wandt VK, Ebert F et al. Toxicological assessment of arsenic-containing phosphatidylcholines in HepG2 cells. Metallomics 12(7), 1159–1170 (2020).
  Medline CASGoogle Scholar
• 63. Haikou MN, Zagana P, Ioannou PV, Antimisiaris SG. Arsonoliposome interaction with thiols: effect of pegylation and arsonolipid content of arsonoliposomes on their integrity during incubation in glutathione. J. Nanosci. Nanotechnol. 6(9–10), 2974–2978 (2006).
  Medline CASGoogle Scholar
• 64. Jin Z, Yi X, Yang J, Zhou M, Wu P, Yan G. Liposome-coated arsenic-manganese complex for magnetic resonance imaging-guided synergistic therapy against carcinoma. Int. J. Nanomed. 16, 3775–3788 (2021).
  MedlineGoogle Scholar
• 65. Wang S, Liu C, Wang C et al. Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency. Asian J. Pharm. Sci. 15(3), 365–373 (2020).
  MedlineGoogle Scholar
• 66. Chen H, Ahn R, Van den Bossche J et al. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer Ther. 8(7), 1955–1963 (2009).
  Medline CASGoogle Scholar
• 67. De R, Mahata MK, Kim KT. Structure-based varieties of polymeric nanocarriers and influences of their physicochemical properties on drug delivery profiles. Adv. Sci. (Weinh) 9(10), e2105373 (2022).
  Medline CASGoogle Scholar
• 68. Iqbal M, Zafar N, Fessi H, Elaissari A. Double emulsion solvent evaporation techniques used for drug encapsulation. Int. J. Pharm. 496(2), 173–190 (2015).
  Medline CASGoogle Scholar
• 69. Wang ZQ, Liu W, Xu HB et al. Preparation and in vitro studies of stealth PEGylated PLGA nanocarriers as carriers for arsenic trioxide. Chin. J. Chem. Eng. 15, 795–801 (2007).
  CASGoogle Scholar
• 70. Singh N, Son S, An J et al. Nanoscale porous organic polymers for drug delivery and advanced cancer theranostics. Chem. Soc. Rev. 50(23), 12883–12896 (2021).
  Medline CASGoogle Scholar
• 71. Chen WH, Chen QW, Chen Q et al. Biomedical polymers: synthesis, properties, and applications. Sci. China Chem. 65(6), 1010–1075 (2022).
  Medline CASGoogle Scholar
• 72. Yin XB, Wu LQ, Huang MW et al. Humanized anti-VEGFR-2 ScFv-ATO-stealth nanocarriers, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity. Biomed. Pharmacother. 68(5), 597–602 (2014).
  Medline CASGoogle Scholar
• 73. Song X, You J, Shao H, Yan C. Effects of surface modification of ATO-loaded PLGA nanocarriers on its anti-liver cancer ability: an in vitro and in vivo study. Colloids Surf. B Biointerfaces 169, 289–297 (2018).
  Medline CASGoogle Scholar
• 74. Song X, Wang J, Xu Y et al. Surface-modified PLGA nanocarriers with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: inhibition effects enhanced and side effects reduced. Colloids Surf. B Biointerfaces 180, 110–117 (2019).
  Medline CASGoogle Scholar
• 75. Lian Y, Wang X, Guo P et al. Erythrocyte membrane-coated arsenic trioxide-loaded sodium alginate nanoparticles for tumor therapy. Pharmaceutics 12(1), 21 (2019).
  MedlineGoogle Scholar
• 76. Bizeau J, Mertz D. Design and applications of protein delivery systems in nanomedicine and tissue engineering. Adv. Colloid Interface Sci. 287, 102334 (2021).
  Medline CASGoogle Scholar
• 77. Iqbal H, Yang T, Li T et al. Serum protein-based nanoparticles for cancer diagnosis and treatment. J. Control. Rel. 329, 997–1022 (2021).
  Medline CASGoogle Scholar
• 78. Lei C, Liu XR, Chen QB et al. Hyaluronic acid and albumin based nanoparticles for drug delivery. J. Control. Rel. 331, 416–433 (2021).
  Medline CASGoogle Scholar
• 79. Cen D, Ge Q, Xie C et al. ZnS@BSA nanoclusters potentiate efficacy of cancer immunotherapy. Adv. Mater. 33(49), e2104037 (2021). • Introduces an arsenic trioxide-based nanoclusters for enhancement of immunotherapy efficacy against hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 80. Ding Y, Zhang S, Sun Z et al. Preclinical validation of silibinin/albumin nanoparticles as an applicable system against acute liver injury. Acta Biomater. 146, 385–395 (2022).
  Medline CASGoogle Scholar
• 81. Zhang N, Mei K, Guan P, Hu X, Zhao Y. Protein-based artificial nanosystems in cancer therapy. Small 16(23), e1907256 (2020).
  Medline CASGoogle Scholar
• 82. Katouzian I, Jafari SM. Protein nanotubes as state-of-the-art nanocarriers: synthesis methods, simulation and applications. J. Control. Rel. 303, 302–318 (2019).
  Medline CASGoogle Scholar
• 83. Miao L, Lin J, Huang Y et al. Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver. Nat. Commun. 11(1), 2424 (2020).
  Medline CASGoogle Scholar
• 84. Yang Z, Yang M, Peng J. Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy. Drug Dev. Ind. Pharm. 34(8), 834–839 (2008).
  Medline CASGoogle Scholar
• 85. Huang Y, Xu Z, Wei Y, Han S, Cai X, Chen D. Albumin-embellished arsenic trioxide-loaded polymeric nanoparticles enhance tumor accumulation and anticancer efficacy via transcytosis for hepatocellular carcinoma therapy. AAPS PharmSciTech 23(4), 111 (2022).
  Medline CASGoogle Scholar
• 86. Zhang K, Li D, Zhou B et al. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC. Biomater. Sci. 10(1), 243–257 (2021).
  Medline CASGoogle Scholar
• 87. Wang C, Zhang W, He Y et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat. Nanotechnol. 16(12), 1413–1423 (2021).
  MedlineGoogle Scholar
• 88. Cioloboc D, Kurtz DM Jr. Targeted cancer cell delivery of arsenate as a reductively activated prodrug. J. Biol. Inorg. Chem. 25(3), 441–449 (2020).
  Medline CASGoogle Scholar
• 89. Khatik R, Wang Z, Zhi D et al. Integrin αvβ3 receptor overexpressing on tumor-targeted positive MRI-guided chemotherapy. ACS Appl. Mater. Interfaces 12(1), 163–176 (2020).
  Medline CASGoogle Scholar
• 90. Yin XB, Wu LQ, Fu HQ et al. Inhibitory effect of humanized anti-VEGFR-2 ScFv-As₂O₃-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies. Asian Pac. J. Trop. Med. 7(5), 337–343 (2014).
  Medline CASGoogle Scholar
• 91. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat. Mater. 8(1), 15–23 (2009).
  Medline CASGoogle Scholar
• 92. Peng Y, Zhao Z, Liu T et al. Smart human-serum-albumin-As₂O₃ nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment. Angew. Chem. Int. Ed. Engl. 56(36), 10845–10849 (2017).
  Medline CASGoogle Scholar
• 93. Kianfar E. Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles. J. Nanobiotechnol. 19(1), 159 (2021).
  Medline CASGoogle Scholar
• 94. Vallet-Regí M, Schüth F, Lozano D et al. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem. Soc. Rev. 51(13), 5365–5451 (2022).
  Medline CASGoogle Scholar
• 95. Escriche-Navarro B, Escudero A, Lucena-Sánchez E et al. Mesoporous silica materials as an emerging tool for cancer immunotherapy. Adv. Sci. 9(26), e2200756 (2022).
  CASGoogle Scholar
• 96. Barkat A, Beg S, Panda SK et al. Functionalized mesoporous silica nanoparticles in anticancer therapeutics. Semin. Cancer Biol. 69, 365–375 (2021).
  Medline CASGoogle Scholar
• 97. Li T, Shi S, Goel S et al. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer. Acta Biomater. 89, 1–13 (2019).
  Medline CASGoogle Scholar
• 98. Xiao X, Liu Y, Guo M et al. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. J. Biomater. Appl. 31(1), 23–35 (2016).
  Medline CASGoogle Scholar
• 99. Fei W, Zhang Y, Han S et al. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma. Int. J. Pharm. 519(1–2), 250–262 (2017).
  Medline CASGoogle Scholar
• 100. Ellison PA, Chen F, Goel S et al. Intrinsic and stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl. Mater. Interfaces 9(8), 6772–6781 (2017).
  Medline CASGoogle Scholar
• 101. Gavilán H, Avugadda SK, Fernández-Cabada T et al. Magnetic nanoparticles and clusters for magnetic hyperthermia: optimizing their heat performance and developing combinatorial therapies to tackle cancer. Chem. Soc. Rev. 50(20), 11614–11667 (2021).
  Medline CASGoogle Scholar
• 102. Chung S, Revia RA, Zhang M. Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy. Nanoscale Horiz. 6(9), 696–717 (2021).
  Medline CASGoogle Scholar
• 103. de la Encarnación C, Jimenez de Aberasturi D, Liz-Marzán LM. Multifunctional plasmonic-magnetic nanoparticles for bioimaging and hyperthermia. Adv. Drug Deliv. Rev. 189, 114484 (2022).
  MedlineGoogle Scholar
• 104. Wang ZY, Song J, Zhang DS. Nanosized As₂O₃/Fe₂O₃ complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J. Gastroenterol. 15(24), 2995–3002 (2009).
  Medline CASGoogle Scholar
• 105. Wu Q, Chen X, Wang P et al. Delivery of arsenic trioxide by multifunction nanoparticles to improve the treatment of hepatocellular carcinoma. ACS Appl. Mater. Interfaces 12(7), 8016–8029 (2020). •• Describes a nano-zirconia loading platform combining chemotherapy and microwave heat therapy for the noninvasive treatment of hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 106. Rathi BS, Kumar PS. A review on sources, identification and treatment strategies for the removal of toxic arsenic from water system. J. Hazard. Mater. 418, 126299 (2021).
  Medline CASGoogle Scholar
• 107. Wang Y, Liu Y, Guo T et al. Lanthanum hydroxide: a highly efficient and selective adsorbent for arsenate removal from aqueous solution. Environ. Sci. Pollut. Res. Int. 27(34), 42868–42880 (2020).
  Medline CASGoogle Scholar
• 108. Zhao Z, Wang X, Zhang Z et al. Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging. ACS Nano 9(3), 2749–2759 (2015). •• Describes a multimodal imaging-guided and multifunctional platform for the treatment of hepatocellular carcinoma.
  Medline CASGoogle Scholar
• 109. Chi X, Yin Z, Jin J et al. Arsenite-loaded nanoparticles inhibit the invasion and metastasis of a hepatocellular carcinoma: in vitro and in vivo study. Nanotechnology 28(44), 445101 (2017).
  MedlineGoogle Scholar
• 110. Klostergaard J, Seeney CE. Magnetic nanovectors for drug delivery. Nanomedicine 8(Suppl. 1), S37–S50 (2012).
  Medline CASGoogle Scholar
• 111. Zhang Z, Liu H, Zhou H et al. A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment. Nanoscale 8(7), 4373–4380 (2016).
  Medline CASGoogle Scholar
• 112. Chi X, Zhang R, Zhao T et al. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma. Nanotechnology 30(17), 175101 (2019).
  Medline CASGoogle Scholar
• 113. Robertson AG, Rendina LM. Gadolinium theranostics for the diagnosis and treatment of cancer. Chem. Soc. Rev. 50(7), 4231–4244 (2021).
  Medline CASGoogle Scholar
• 114. Li H, Zeng Y, Zhang H, Gu Z, Gong Q, Luo K. Functional gadolinium-based nanoscale systems for cancer theranostics. J. Control. Rel. 329, 482–512 (2021).
  Medline CASGoogle Scholar
• 115. Ji Y, Kowalski PM, Kegler P et al. Rare-earth orthophosphates from atomistic simulations. Front. Chem. 7, 197 (2019).
  Medline CASGoogle Scholar
• 116. Wang P, He X, Zhang W et al. Highly efficient removal of p-arsanilic acid with Fe(II)/peroxydisulfate under near-neutral conditions. Water Res. 177, 115752 (2020).
  Medline CASGoogle Scholar
• 117. Khatik R, Wang Z, Zhi D et al. Integrin αvβ3 receptor overexpressing on tumor-targeted positive MRI-guided chemotherapy. ACS Appl. Mater. Interfaces 12(1), 163–176 (2020).
  Medline CASGoogle Scholar
• 118. Fu X, Luo RG, Qiu W et al. Sustained release of arsenic trioxide benefits interventional therapy on rabbit VX2 liver tumor. Nanomedicine 24, 102118 (2020).
  Medline CASGoogle Scholar
• 119. Bi QC, Tang JJ, Zhao J et al. Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization. Drug Deliv. 29(1), 1447–1456 (2022).
  Medline CASGoogle Scholar
• 120. Huang Y, Zhou B, Luo H et al. ZnAs@SiO₂ nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics 9(15), 4391–4408 (2019).
  Medline CASGoogle Scholar
• 121. Mottaghitalab F, Farokhi M, Fatahi Y et al. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J. Control. Rel. 295, 250–267 (2019).
  Medline CASGoogle Scholar
• 122. Liao Y, Zhang Y, Blum NT et al. Biomimetic hybrid membrane-based nanoplatforms: synthesis, properties and biomedical applications. Nanoscale Horiz. 5(9), 1293–1302 (2020).
  Medline CASGoogle Scholar
• 123. Wei D, Yang H, Zhang Y et al. Nano-traditional Chinese medicine: a promising strategy and its recent advances. J. Mater. Chem. B 10(16), 2973–2994 (2022).
  Medline CASGoogle Scholar
• 124. Biddeci G, Spinelli G, Colomba P, Di Blasi F. Nanomaterials: a review about halloysite nanotubes, properties, and application in the biological field. Int. J. Mol. Sci. 23(19), 11518 (2022).
  Medline CASGoogle Scholar
• 125. Yang C, Lin ZI, Chen JA et al. Organic/inorganic self-assembled hybrid nano-architectures for cancer therapy applications. Macromol. Biosci. 22(2), e2100349 (2022).
  Medline CASGoogle Scholar
• 126. Ding X, Li D, Jiang J. Gold-based inorganic nanohybrids for nanomedicine applications. Theranostics 10(18), 8061–8079 (2020).
  Medline CASGoogle Scholar
• 127. Birk SE, Boisen A, Nielsen LH. Polymeric nano- and microparticulate drug delivery systems for treatment of biofilms. Adv. Drug. Deliv. Rev. 174, 30–52 (2021).
  Medline CASGoogle Scholar
• 128. Timin AS, Litvak MM, Gorin DA et al. Cell-based drug delivery and use of nano-and microcarriers for cell functionalization. Adv. Healthc. Mater. 7(3), 1700818 (2018).
  Google Scholar
• 129. Shait Mohammed MR, Ahmad V, Ahmad A et al. Prospective of nanoscale metal organic frameworks [NMOFs] for cancer therapy. Semin. Cancer Biol. 69, 129–139 (2021).
  MedlineGoogle Scholar
• 130. Li Q, Liu Y, Zhang Y, Jiang W. Immunogenicity-boosted cancer immunotherapy based on nanoscale metal-organic frameworks. J. Control. Rel. 347, 183–198 (2022).
  Medline CASGoogle Scholar
• 131. Esrafili A, Wagner A, Inamdar S, Acharya AP. Covalent organic frameworks for biomedical applications. Adv. Healthc. Mater. 10(6), e2002090 (2021).
  Medline CASGoogle Scholar
• 132. Yang J, Yang YW. Metal-organic frameworks for biomedical applications. Small 16(10), e1906846 (2020).
  Medline CASGoogle Scholar
• 133. Chen X, Huang Y, Chen H et al. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8 nanoparticles on residual HCC progression. J. Nanobiotechnol. 20(1), 34 (2022).
  Medline CASGoogle Scholar
• 134. Wu Y, Du D, Chen J, Liu C. Preparation of PLGA microspheres loaded with 10-hydroxycamptothecin and arsenic trioxide and their treatment for rabbit hepatocellular carcinoma. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 165(1), 57–63 (2021).
  MedlineGoogle Scholar
• 135. Liu H, Zhang Z, Chi X et al. Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells. Sci. Rep. 6, 31009 (2016).
  Medline CASGoogle Scholar
• 136. Zhi D, Yang T, O'Hagan J et al. Photothermal therapy. J. Control. Rel. 325, 52–71 (2020).
  Medline CASGoogle Scholar
• 137. Li L, Zhang X, Zhou J et al. Non-invasive thermal therapy for tissue engineering and regenerative medicine. Small 18(36), e2107705 (2022).
  Medline CASGoogle Scholar
• 138. Xu Q, Li Q, Yang Z et al. Lenvatinib and Cu_2-xS nanocrystals co-encapsulated in poly(D,L-lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma. J. Mater. Chem. B 9(48), 9908–9922 (2021).
  Medline CASGoogle Scholar
• 139. Fan Z, Zhuang C, Wang S, Zhang Y. Photodynamic and photothermal therapy of hepatocellular carcinoma. Front. Oncol. 11, 787780 (2021).
  MedlineGoogle Scholar
• 140. Wang ZY, Wang L, Zhang J et al. A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors. Int. J. Nanomed. 6, 871–875 (2011).
  Medline CASGoogle Scholar
• 141. Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics-challenges and potential solutions. Nat. Rev. Drug Discov. 20(8), 629–651 (2021).
  Medline CASGoogle Scholar
• 142. Wei L, Wang X, Lv L et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol. Cancer 18(1), 147 (2019).
  MedlineGoogle Scholar
• 143. Hill M, Tran N. MiRNA interplay: mechanisms and consequences in cancer. Dis Model. Mech. 14(4), dmm047662 (2021).
  Medline CASGoogle Scholar
• 144. Kim T, Croce CM. MicroRNA and ER stress in cancer. Semin. Cancer Biol. 75, 3–14 (2021).
  Medline CASGoogle Scholar
• 145. Mukherjee A, Acharya PB, Singh A et al. Identification of therapeutic miRNAs from the arsenic induced gene expression profile of hepatocellular carcinoma. Chem. Biol. Drug Des. 10.1111/cbdd.14132 (2022).
  Google Scholar
• 146. Zhu C, Zhou R, Zhou Q et al. MicroRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma. Life Sci. 166, 34–40 (2016).
  Medline CASGoogle Scholar
• 147. Wang Y, Jiang F, Jiao K et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties. Exp. Cell Res. 386(2), 111739 (2020).
  Medline CASGoogle Scholar
• 148. Hu J, Pei W, Jiang Z et al. A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation. Cancer Nano. 12, 1 (2021).
  MedlineGoogle Scholar
• 149. Llovet JM, Castet F, Heikenwalder M et al. Immunotherapies for hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 19(3), 151–172 (2022).
  Medline CASGoogle Scholar
• 150. Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular carcinoma immunotherapy. Annu. Rev. Med. 73, 267–278 (2022).
  MedlineGoogle Scholar
• 151. Yu WD, Sun G, Li J et al. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 452, 66–70 (2019).
  Medline CASGoogle Scholar
• 152. Yap TA, Parkes EE, Peng W et al. Development of immunotherapy combination strategies in cancer. Cancer Discov. 11(6), 1368–1397 (2021).
  Medline CASGoogle Scholar
• 153. Luo L, Qiao H, Meng F et al. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas. Int. J. Cancer 118(7), 1823–1830 (2006).
  Medline CASGoogle Scholar
• 154. Zhai Y, Liu M, Yang T et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy. J. Control. Rel. 350, 761–776 (2022).
  Medline CASGoogle Scholar
• 155. Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65(1), 80–88 (2013).
  Medline CASGoogle Scholar
• 156. Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol. Ther. 173, 106–117 (2017).
  Medline CASGoogle Scholar
• 157. Duan XH, Ju SG, Han XW et al. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients. Eur. Rev. Med. Pharmacol. Sci. 24(3), 1468–1480 (2020).
  MedlineGoogle Scholar
• 158. Liu J, Zhang W, Lu H et al. Drug-eluting bead trans-arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value. J. Cancer Res. Clin. Oncol. 148(7), 1781–1788 (2022).
  Medline CASGoogle Scholar
• 159. Kong D, Jiang T, Liu J et al. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal. Drug Deliv. 27(1), 1729–1740 (2020).
  Medline CASGoogle Scholar
• 160. Hu J, Dong Y, Ding L et al. Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment. Signal Transduct. Target. Ther. 4, 28 (2019).
  MedlineGoogle Scholar
• 161. Duan X, Li H, Han X et al. Antitumor properties of arsenic trioxide-loaded CalliSpheres^® microspheres by transarterial chemoembolization in VX2 liver tumor rabbits: suppression of tumor growth, angiogenesis, and metastasis and elongation of survival. Am. J. Transl. Res. 12(9), 5511–5524 (2020).
  Medline CASGoogle Scholar